StageZero Life Sciences Announces Change of Date of Special Meeting of Shareholders; Will Combine with AGM in Q2 2023
Toronto, Ontario--(Newsfile Corp. - February 2, 2023) - StageZero Life Sciences, Ltd. (TSX: SZLS) (OTCQB: SZLSF) ("StageZero" or the "Company"), a vertically integrated healthcare company devoted to improving the early detection and management of cancer and other chronic diseases through leading-edge molecular diagnostics and clinical interventions, announced today that its special meeting (the "Meeting") originally scheduled for Tuesday February 28, will now be combined with the Annual General Meeting ("AGM") in Q2 2023.
At the proposed Meeting, shareholders were to be asked to vote on two resolutions:
- Approval to issue common shares pursuant to the Capital Commitment Agreement with GEM Global Yield in excess of 25% of the issued and outstanding common shares; and
- Approval to issue common shares to a director, in excess of 10% of the issued and outstanding common shares, as conversion of short term notes.
Management has determined that these resolutions are not sufficiently urgent in nature to warrant a special meeting at this time. Therefore, the special meeting will be combined with the Annual General Meeting for shareholders and the resolutions will be voted on at that time. Combining the two meetings will offer a more efficient and cost effective option for the Company.
When the date and time for the Special and Annual General Meeting has been determined, the Company will file proxy materials containing the necessary and appropriate information, including the record date determining which stockholders are eligible to vote at the Meeting.
About StageZero Life Sciences, Ltd.
StageZero Life Sciences, Ltd. is a vertically integrated healthcare company dedicated to improving the early detection and management of cancer and other chronic diseases through next-generation diagnostics and a unique telehealth program that provides clinical interventions to help patients reduce the risk of developing late-stage disease (AVRT™).
The Company's next generation test, Aristotle®, is the first ever mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle® uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. This underlying technology has been validated in more than 9,000 patients and used by more than 100,000 patients in North America.
Aristotle®, as well as additional cancer diagnostics (ColonSentry®, BreastSentry™, and the Prostate Health Index) are processed at the Company's clinical laboratory, StageZero Life Sciences, Inc., a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, the Company is also leveraging its specialty in polymerase chain reaction (PCR) testing to provide COVID-19 PCR testing (swab and saliva) and Antibody Testing (blood analysis).
StageZero Life Sciences trades on the Toronto Stock exchange under the symbol SZLS and on the OTCQB under the symbol SZLSF.
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
1-855-420-7140 ext. 1838
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/153433